TP53 and acute myeloid leukemia: Combined Magrolimab and AZA was assessed in the treatment TP53 mutated AML patients (n = 9) resulting in a CR/Cri of 78% and 44%, respectively and negative MRD in 57% of the responders, with a median follow up of 6.9 months.